{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:43:21Z","timestamp":1793234601579,"version":"4.5.0"},"reference-count":207,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Malignant melanoma is responsible for most skin cancer\u2013related deaths due to its unpredictable behavior. Serum biomarkers have been widely investigated to improve prognostic assessment, yet their clinical utility remains inconclusive. This systematic review and meta-analysis evaluated the prognostic significance of serum biomarkers in melanoma. Following PRISMA guidelines and a registered protocol (PROSPERO: CRD42023486532), PubMed, EMBASE, and CENTRAL were searched for studies assessing biomarkers and survival outcomes. Univariate analyses revealed that elevated levels of LDH (HR 2.29, 95%-CI:1.97\u20132.67), S100B (HR 2.52, 95%-CI:1.59\u20133.99), circulating tumor DNA (ctDNA) (HR 2.61, 95%-CI:1.90\u20133.58), neutrophil-to-lymphocyte ratio (NLR) (HR 2.34, 95%-CI:1.86\u20132.93), and interleukin-6 (HR 3.11, 95%-CI:2.44\u20133.96) were significantly associated with reduced overall survival. Similarly, higher levels of LDH (HR 2.04, 95%-CI:1.68\u20132.47), S100B (HR 1.94, 95%-CI:1.39\u20132.70), ctDNA (HR 2.57, 95%-CI:1.95\u20133.39), and NLR (HR 2.38, 95%-CI:1.52\u20133.73) predicted shorter progression-free survival. These associations persisted in multivariable-adjusted analyses for LDH, ctDNA, NLR, IL-6, S100B, and CRP supporting their predictive relevance. LDH remains a reliable and cost-effective biomarker, while NLR may provide complementary prognostic information in patients receiving immune checkpoint inhibitors. Emerging biomarkers such as ctDNA demonstrate promising prognostic potential, but further evaluation is required before routine clinical implementation.<\/jats:p>","DOI":"10.1038\/s41598-026-54347-w","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:05:10Z","timestamp":1780931110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive value of serum biomarkers for survival in melanoma: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Lili","family":"Guly\u00e1s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni Ad\u00e9l","family":"Meznerics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi N\u00f3ra","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos Vince","family":"Kem\u00e9ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"\u00c9rseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"B\u00e1nv\u00f6lgyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kende K\u00e1lm\u00e1n","family":"L\u0151rincz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"54347_CR1","unstructured":"Society, A. C. Key statistics for melanoma skin cancer, https:\/\/www.cancer.org\/cancer\/types\/melanoma-skin-cancer\/about\/key-statistics.html (2024)."},{"key":"54347_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold, M. et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 158, 495\u2013503. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0160 (2022).","journal-title":"JAMA Dermatol."},{"key":"54347_CR3","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1111\/ijd.17851","volume":"64","author":"RC Bueno-Molina","year":"2025","unstructured":"Bueno-Molina, R. C. et al. Geospatial analysis of cutaneous malignant melanoma epidemiology in Europe from 2017 to 2021. Int. J. Dermatol. 64, 2054\u20132063. https:\/\/doi.org\/10.1111\/ijd.17851 (2025).","journal-title":"Int. J. Dermatol."},{"key":"54347_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9040063","author":"K Saginala","year":"2021","unstructured":"Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P. & Barsouk, A. Epidemiology of melanoma. Med. Sci. https:\/\/doi.org\/10.3390\/medsci9040063 (2021).","journal-title":"Med. Sci."},{"key":"54347_CR5","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R. & Keilholz, U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up &#x2020;. Ann. Oncol. 30, 1884\u20131901. https:\/\/doi.org\/10.1093\/annonc\/mdz411 (2019).","journal-title":"Ann. Oncol."},{"key":"54347_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald, J. E. et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 472\u2013492. https:\/\/doi.org\/10.3322\/caac.21409 (2017).","journal-title":"CA Cancer J Clin"},{"key":"54347_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2017.11.023","volume":"91","author":"JJ Grob","year":"2018","unstructured":"Grob, J. J. et al. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. Eur. J. Cancer 91, 168\u2013170. https:\/\/doi.org\/10.1016\/j.ejca.2017.11.023 (2018).","journal-title":"Eur. J. Cancer"},{"key":"54347_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.772165","author":"EA Janka","year":"2021","unstructured":"Janka, E. A. et al. Predictive performance of serum S100B versus LDH in melanoma patients: A systematic review and meta-analysis. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.772165 (2021).","journal-title":"Front. Oncol."},{"key":"54347_CR9","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1002\/ijc.23794","volume":"123","author":"S Mocellin","year":"2008","unstructured":"Mocellin, S., Zavagno, G. & Nitti, D. The prognostic value of serum S100B in patients with cutaneous melanoma: A meta-analysis. Int. J. Cancer 123, 2370\u20132376. https:\/\/doi.org\/10.1002\/ijc.23794 (2008).","journal-title":"Int. J. Cancer"},{"key":"54347_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biom13030529","author":"M Salzmann","year":"2023","unstructured":"Salzmann, M., Enk, A. H. & Hassel, J. C. S100 as serum tumor marker in advanced uveal melanoma. Biomolecules https:\/\/doi.org\/10.3390\/biom13030529 (2023).","journal-title":"Biomolecules"},{"key":"54347_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103187","author":"S Gandini","year":"2021","unstructured":"Gandini, S. et al. Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis. Crit. Rev. Oncol. Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103187 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"54347_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040859","author":"Y Shoji","year":"2022","unstructured":"Shoji, Y., Bustos, M. A., Gross, R. & Hoon, D. S. B. Recent developments of circulating tumor cell analysis for monitoring cutaneous melanoma patients. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14040859 (2022).","journal-title":"Cancers (Basel)"},{"key":"54347_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ctrv.2018.09.005","volume":"71","author":"A Tarhini","year":"2018","unstructured":"Tarhini, A. & Kudchadkar, R. R. Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. Cancer Treat. Rev. 71, 8\u201318. https:\/\/doi.org\/10.1016\/j.ctrv.2018.09.005 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"54347_CR14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1126\/science.aaf2834","volume":"352","author":"CU Blank","year":"2016","unstructured":"Blank, C. U., Haanen, J. B., Ribas, A. & Schumacher, T. N. Cancer immunology. The \u201ccancer immunogram\u201d. Science 352, 658\u2013660. https:\/\/doi.org\/10.1126\/science.aaf2834 (2016).","journal-title":"Science"},{"key":"54347_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ https:\/\/doi.org\/10.1136\/bmj.n71 (2021).","journal-title":"BMJ"},{"key":"54347_CR16","unstructured":"Higgins JPT, T. J., Chandler J, Cumpston M, Li T, Page MJ, Welch VA. (Cochrane, 2023)."},{"key":"54347_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","volume":"104","author":"WM Bramer","year":"2016","unstructured":"Bramer, W. M., Giustini, D., de Jonge, G. B., Holland, L. & Bekhuis, T. De-duplication of database search results for systematic reviews in EndNote. J. Med. Libr. Assoc. 104, 240\u2013243. https:\/\/doi.org\/10.3163\/1536-5050.104.3.014 (2016).","journal-title":"J. Med. Libr. Assoc."},{"key":"54347_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan\u2014A web and mobile app for systematic reviews. Syst. Rev. 5, 210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4 (2016).","journal-title":"Syst. Rev."},{"key":"54347_CR19","unstructured":"Group, C. P. M. Tools and guidance for assessing risk of bias in prognosis studies, https:\/\/methods.cochrane.org\/prognosis\/risk-bias-tools"},{"key":"54347_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","author":"JF Tierney","year":"2007","unstructured":"Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials https:\/\/doi.org\/10.1186\/1745-6215-8-16 (2007).","journal-title":"Trials"},{"key":"54347_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki, A. A. et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res. Synth. Methods 7, 55\u201379. https:\/\/doi.org\/10.1002\/jrsm.1164 (2016).","journal-title":"Res. Synth. Methods"},{"key":"54347_CR22","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"Doing Meta-Analysis with R: A Hands-On Guide","author":"M Harrer","year":"2021","unstructured":"Harrer, M., Cuijpers, P., Furukawa, T. A. & Ebert, D. D. Doing Meta-Analysis with R: A Hands-On Guide (Chapman & Hall\/CRC Press, 2021)."},{"key":"54347_CR23","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins, J. P. T. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186 (2002).","journal-title":"Stat. Med."},{"key":"54347_CR24","unstructured":"R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2024)."},{"key":"54347_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi, S., R\u00fccker, G. & Schwarzer, G. How to perform a meta-analysis with R: A practical tutorial. Evid. Based Ment. Health 22, 153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117 (2019).","journal-title":"Evid. Based Ment. Health"},{"key":"54347_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. J. Stat. Softw. 36, 1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03 (2010).","journal-title":"J. Stat. Softw."},{"key":"54347_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep09800","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: A systematic review and meta-analysis. Sci. Rep. https:\/\/doi.org\/10.1038\/srep09800 (2015).","journal-title":"Sci. Rep."},{"key":"54347_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie, G. J. et al. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit. Rev. Oncol. Hematol. 88, 218\u2013230. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.03.010 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"54347_CR29","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1002\/jmv.26654","volume":"93","author":"EA Said","year":"2021","unstructured":"Said, E. A. et al. Defining IL-6 levels in healthy individuals: A meta-analysis. J. Med. Virol. 93, 3915\u20133924. https:\/\/doi.org\/10.1002\/jmv.26654 (2021).","journal-title":"J. Med. Virol."},{"key":"54347_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/ijc.33768","volume":"150","author":"E Aamdal","year":"2022","unstructured":"Aamdal, E. et al. Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. Int. J. Cancer 150, 100\u2013111. https:\/\/doi.org\/10.1002\/ijc.33768 (2022).","journal-title":"Int. J. Cancer"},{"key":"54347_CR31","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/s0959-8049(03)00372-1","volume":"39","author":"V Chiarion-Sileni","year":"2003","unstructured":"Chiarion-Sileni, V. et al. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur. J. Cancer 39, 1577\u20131585. https:\/\/doi.org\/10.1016\/s0959-8049(03)00372-1 (2003).","journal-title":"Eur. J. Cancer"},{"key":"54347_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/sj.bjc.6602702","volume":"93","author":"H Schmidt","year":"2005","unstructured":"Schmidt, H. et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: A prognostic model. Br. J. Cancer 93, 273\u2013278. https:\/\/doi.org\/10.1038\/sj.bjc.6602702 (2005).","journal-title":"Br. J. Cancer"},{"key":"54347_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00008390-200510000-00009","volume":"15","author":"H Schmidt","year":"2005","unstructured":"Schmidt, H., Sorensen, B. S., Fode, K., Nexo, E. & von der Maase, H. Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res. 15, 409\u2013416. https:\/\/doi.org\/10.1097\/00008390-200510000-00009 (2005).","journal-title":"Melanoma Res."},{"key":"54347_CR34","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1245\/s10434-007-9448-y","volume":"14","author":"HB Neuman","year":"2007","unstructured":"Neuman, H. B. et al. Stage-IV melanoma and pulmonary metastases: Factors predictive of survival. Ann. Surg. Oncol. 14, 2847\u20132853. https:\/\/doi.org\/10.1245\/s10434-007-9448-y (2007).","journal-title":"Ann. Surg. Oncol."},{"key":"54347_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/CMR.0b013e32832ec001","volume":"19","author":"P Vereecken","year":"2009","unstructured":"Vereecken, P. et al. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res. 19, 316\u2013320. https:\/\/doi.org\/10.1097\/CMR.0b013e32832ec001 (2009).","journal-title":"Melanoma Res."},{"key":"54347_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/CMR.0b013e3283550aa5","volume":"22","author":"L Hoejberg","year":"2012","unstructured":"Hoejberg, L. et al. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res. 22, 287\u2013293. https:\/\/doi.org\/10.1097\/CMR.0b013e3283550aa5 (2012).","journal-title":"Melanoma Res."},{"key":"54347_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1148\/radiol.13130776","volume":"270","author":"MR Gray","year":"2014","unstructured":"Gray, M. R. et al. Metastatic melanoma: Lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab. Radiology 270, 425\u2013434. https:\/\/doi.org\/10.1148\/radiol.13130776 (2014).","journal-title":"Radiology"},{"key":"54347_CR38","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/jco.2014.58.0209","volume":"33","author":"S Fang","year":"2015","unstructured":"Fang, S. et al. C-reactive protein as a marker of melanoma progression. J. Clin. Oncol. 33, 1389\u20131396. https:\/\/doi.org\/10.1200\/jco.2014.58.0209 (2015).","journal-title":"J. Clin. Oncol."},{"key":"54347_CR39","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray, E. S. et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6, 42008\u201342018. https:\/\/doi.org\/10.18632\/oncotarget.5788 (2015).","journal-title":"Oncotarget"},{"key":"54347_CR40","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1158\/0008-5472.CAN-15-2303","volume":"75","author":"Y Koguchi","year":"2015","unstructured":"Koguchi, Y. et al. Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with Ipilimumab. Cancer Res. 75, 5084\u20135092. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2303 (2015).","journal-title":"Cancer Res."},{"key":"54347_CR41","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/annonc\/mdu573","volume":"26","author":"S Ugurel","year":"2015","unstructured":"Ugurel, S. et al. A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: Pretreatment impacts survival. Ann. Oncol. 26, 573\u2013582. https:\/\/doi.org\/10.1093\/annonc\/mdu573 (2015).","journal-title":"Ann. Oncol."},{"key":"54347_CR42","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/cmr.0000000000000269","volume":"26","author":"R H\u00fcgel","year":"2016","unstructured":"H\u00fcgel, R. et al. Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma. Melanoma Res. 26, 354\u2013360. https:\/\/doi.org\/10.1097\/cmr.0000000000000269 (2016).","journal-title":"Melanoma Res."},{"key":"54347_CR43","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","volume":"34","author":"GV Long","year":"2016","unstructured":"Long, G. V. et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving Dabrafenib combined with Trametinib. J. Clin. Oncol. 34, 871\u2013878. https:\/\/doi.org\/10.1200\/JCO.2015.62.9345 (2016).","journal-title":"J. Clin. Oncol."},{"key":"54347_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bjd.14155","volume":"174","author":"J Zaragoza","year":"2016","unstructured":"Zaragoza, J. et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br. J. Dermatol. 174, 146\u2013151. https:\/\/doi.org\/10.1111\/bjd.14155 (2016).","journal-title":"Br J Dermatol"},{"key":"54347_CR45","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/ijc.30498","volume":"140","author":"A Desch","year":"2017","unstructured":"Desch, A., Gebhardt, C., Utikal, J. & Schneider, S. W. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress. Int. J. Cancer 140, 914\u2013921. https:\/\/doi.org\/10.1002\/ijc.30498 (2017).","journal-title":"Int. J. Cancer"},{"key":"54347_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11523-017-0491-8","volume":"12","author":"F Garlan","year":"2017","unstructured":"Garlan, F. et al. Circulating tumor DNA measurement by picoliter droplet-based digital PCR and Vemurafenib plasma concentrations in patients with advanced BRAF-mutated melanoma. Target. Oncol. 12, 365\u2013371. https:\/\/doi.org\/10.1007\/s11523-017-0491-8 (2017).","journal-title":"Target. Oncol."},{"key":"54347_CR47","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s10637-017-0476-6","volume":"35","author":"V Heidelberger","year":"2017","unstructured":"Heidelberger, V. et al. Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. Invest. N. Drugs 35, 842\u2013847. https:\/\/doi.org\/10.1007\/s10637-017-0476-6 (2017).","journal-title":"Invest. New Drugs"},{"key":"54347_CR48","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee, J. H. et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann. Oncol. 28, 1130\u20131136. https:\/\/doi.org\/10.1093\/annonc\/mdx026 (2017).","journal-title":"Ann. Oncol."},{"key":"54347_CR49","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.tranon.2017.06.004","volume":"10","author":"J Yu","year":"2017","unstructured":"Yu, J. et al. Systemic immune-inflammation index and circulating T-Cell immune index predict outcomes in high-risk acral melanoma patients treated with high-dose Interferon. Transl. Oncol. 10, 719\u2013725. https:\/\/doi.org\/10.1016\/j.tranon.2017.06.004 (2017).","journal-title":"Transl. Oncol."},{"key":"54347_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone, M. et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with Nivolumab. J. Immunother. Cancer 6, 74. https:\/\/doi.org\/10.1186\/s40425-018-0383-1 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"54347_CR51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1684\/ejd.2017.3167","volume":"28","author":"A Finon","year":"2018","unstructured":"Finon, A. et al. A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma. Eur. J. Dermatol. 28, 38\u201343. https:\/\/doi.org\/10.1684\/ejd.2017.3167 (2018).","journal-title":"Eur. J. Dermatol."},{"key":"54347_CR52","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/cmr.0000000000000432","volume":"28","author":"M Gonzalez-Cao","year":"2018","unstructured":"Gonzalez-Cao, M. et al. Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. Melanoma Res. 28, 195\u2013203. https:\/\/doi.org\/10.1097\/cmr.0000000000000432 (2018).","journal-title":"Melanoma Res."},{"key":"54347_CR53","doi-asserted-by":"publisher","first-page":"25265","DOI":"10.18632\/oncotarget.25404","volume":"9","author":"G Herbreteau","year":"2018","unstructured":"Herbreteau, G. et al. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget 9, 25265\u201325276. https:\/\/doi.org\/10.18632\/oncotarget.25404 (2018).","journal-title":"Oncotarget"},{"key":"54347_CR54","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/annonc\/mdx717","volume":"29","author":"RJ Lee","year":"2018","unstructured":"Lee, R. J. et al. Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma. Ann. Oncol. 29, 490\u2013496. https:\/\/doi.org\/10.1093\/annonc\/mdx717 (2018).","journal-title":"Ann. Oncol."},{"key":"54347_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00168","volume":"2","author":"W Lu","year":"2018","unstructured":"Lu, W. et al. Elevated levels of BRAF(V600) mutant circulating tumor DNA and circulating hepatocyte growth factor are associated with poor prognosis in patients with metastatic melanoma. JCO Precis Oncol. 2, 1\u201317. https:\/\/doi.org\/10.1200\/po.17.00168 (2018).","journal-title":"JCO Precis Oncol."},{"key":"54347_CR56","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/cam4.1356","volume":"7","author":"S Rosner","year":"2018","unstructured":"Rosner, S. et al. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Med. 7, 690\u2013697. https:\/\/doi.org\/10.1002\/cam4.1356 (2018).","journal-title":"Cancer Med."},{"key":"54347_CR57","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00262-019-02303-1","volume":"68","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih, H. et al. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol. Immunother. 68, 553\u2013561. https:\/\/doi.org\/10.1007\/s00262-019-02303-1 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"54347_CR58","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1080\/0284186x.2019.1620966","volume":"58","author":"A Arheden","year":"2019","unstructured":"Arheden, A. et al. Real-world data on PD-1 inhibitor therapy in metastatic melanoma. Acta Oncol. 58, 962\u2013966. https:\/\/doi.org\/10.1080\/0284186x.2019.1620966 (2019).","journal-title":"Acta Oncol."},{"key":"54347_CR59","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1093\/neuonc\/noz141","volume":"21","author":"A Bhatia","year":"2019","unstructured":"Bhatia, A. et al. MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors. Neuro. Oncol. 21, 1578\u20131586. https:\/\/doi.org\/10.1093\/neuonc\/noz141 (2019).","journal-title":"Neuro. Oncol."},{"key":"54347_CR60","doi-asserted-by":"publisher","unstructured":"Czirbesz, K. et al. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data. Pathol. Oncol. Res. 25, 45\u201350. https:\/\/doi.org\/10.1007\/s12253-017-0324-1 (2019).","DOI":"10.1007\/s12253-017-0324-1"},{"key":"54347_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53917-5","author":"RB Forthun","year":"2019","unstructured":"Forthun, R. B. et al. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-019-53917-5 (2019).","journal-title":"Sci. Rep."},{"key":"54347_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2019.108688","author":"A Schraag","year":"2019","unstructured":"Schraag, A. et al. Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy. Eur. J. Radiol. https:\/\/doi.org\/10.1016\/j.ejrad.2019.108688 (2019).","journal-title":"Eur. J. Radiol."},{"key":"54347_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-2051-8","author":"T Seremet","year":"2019","unstructured":"Seremet, T. et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J. Transl. Med. https:\/\/doi.org\/10.1186\/s12967-019-2051-8 (2019).","journal-title":"J. Transl. Med."},{"key":"54347_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000333","author":"T Amaral","year":"2020","unstructured":"Amaral, T. et al. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2019-000333 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"54347_CR65","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/po.19.00174","volume":"4","author":"J Braune","year":"2020","unstructured":"Braune, J. et al. Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. JCO Precis Oncol. 4, 20\u201331. https:\/\/doi.org\/10.1200\/po.19.00174 (2020).","journal-title":"JCO Precis Oncol"},{"key":"54347_CR66","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1007\/s12094-020-02320-y","volume":"22","author":"E Cocorocchio","year":"2020","unstructured":"Cocorocchio, E. et al. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors. Clin. Transl. Oncol. 22, 1818\u20131824. https:\/\/doi.org\/10.1007\/s12094-020-02320-y (2020).","journal-title":"Clin. Transl. Oncol."},{"key":"54347_CR67","doi-asserted-by":"publisher","DOI":"10.1177\/0300891619900928","author":"K Kozak","year":"2020","unstructured":"Kozak, K. et al. Cell-free DNA BRAF V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysis. Tumori https:\/\/doi.org\/10.1177\/0300891619900928 (2020).","journal-title":"Tumori"},{"key":"54347_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000842","author":"AS Laino","year":"2020","unstructured":"Laino, A. S. et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-000842 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"54347_CR69","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1158\/1078-0432.Ccr-19-3926","volume":"26","author":"JH Lee","year":"2020","unstructured":"Lee, J. H. et al. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. Clin. Cancer Res. 26, 4064\u20134071. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-3926 (2020).","journal-title":"Clin. Cancer Res."},{"key":"54347_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75792-1","volume":"10","author":"GT Marczynski","year":"2020","unstructured":"Marczynski, G. T., Laus, A. C., Dos Reis, M. B., Reis, R. M. & Vazquez, V. L. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. Sci. Rep. 10, 18682. https:\/\/doi.org\/10.1038\/s41598-020-75792-1 (2020).","journal-title":"Sci. Rep."},{"key":"54347_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061414","author":"JG Pedersen","year":"2020","unstructured":"Pedersen, J. G. et al. Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12061414 (2020).","journal-title":"Cancers (Basel)"},{"key":"54347_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-020-00322-1","author":"CP Reinert","year":"2020","unstructured":"Reinert, C. P. et al. Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing (18)F-FDG-PET\/CT: A comparison with serologic markers of tumor burden and inflammation. Cancer Imaging https:\/\/doi.org\/10.1186\/s40644-020-00322-1 (2020).","journal-title":"Cancer Imaging"},{"key":"54347_CR73","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.21873\/anticanres.14175","volume":"40","author":"L Simeti\u0107","year":"2020","unstructured":"Simeti\u0107, L., Bla\u017ei\u010devi\u0107, K., Me\u0111ugorac, K., Gol\u010di\u0107, M. & Herceg, D. Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab. Anticancer Res. 40, 2157\u20132163. https:\/\/doi.org\/10.21873\/anticanres.14175 (2020).","journal-title":"Anticancer Res."},{"key":"54347_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001689","author":"R Turiello","year":"2020","unstructured":"Turiello, R. et al. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-001689 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"54347_CR75","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1002\/ijc.33162","volume":"147","author":"MCT van Zeijl","year":"2020","unstructured":"van Zeijl, M. C. T. et al. Real-world outcomes of advanced melanoma patients not represented in phase III trials. Int. J. Cancer 147, 3461\u20133470. https:\/\/doi.org\/10.1002\/ijc.33162 (2020).","journal-title":"Int. J. Cancer"},{"key":"54347_CR76","doi-asserted-by":"publisher","unstructured":"V\u00e1raljai, R. et al. Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. JCO Precis Oncol. 3 (2020). https:\/\/doi.org\/10.1200\/po.18.00229","DOI":"10.1200\/po.18.00229"},{"key":"54347_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020168","author":"G Awada","year":"2021","unstructured":"Awada, G. et al. A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13020168 (2021).","journal-title":"Cancers (Basel)"},{"key":"54347_CR78","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11523-021-00792-8","volume":"16","author":"M Gassenmaier","year":"2021","unstructured":"Gassenmaier, M. et al. Serum S100B and LDH at baseline and during therapy predict the outcome of metastatic melanoma patients treated with BRAF inhibitors. Target. Oncol. 16, 197\u2013205. https:\/\/doi.org\/10.1007\/s11523-021-00792-8 (2021).","journal-title":"Target. Oncol."},{"key":"54347_CR79","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/jdv.16678","volume":"35","author":"I Krakowski","year":"2021","unstructured":"Krakowski, I. et al. Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting. J. Eur. Acad. Dermatol. Venereol. 35, 105\u2013115. https:\/\/doi.org\/10.1111\/jdv.16678 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"54347_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001642","author":"AAN Rose","year":"2021","unstructured":"Rose, A. A. N. et al. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. J. Immunother. Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001642 (2021).","journal-title":"J. Immunother. Cancer."},{"key":"54347_CR81","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(20)30726-9","volume":"22","author":"MM Syeda","year":"2021","unstructured":"Syeda, M. M. et al. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: A clinical validation study. Lancet. Oncol. 22, 370\u2013380. https:\/\/doi.org\/10.1016\/S1470-2045(20)30726-9 (2021).","journal-title":"Lancet. Oncol."},{"key":"54347_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153913","author":"SH Tolmeijer","year":"2021","unstructured":"Tolmeijer, S. H. et al. Plasma BRAF mutation detection for the diagnostic and monitoring trajectory of patients with LDH-High stage IV melanoma. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13153913 (2021).","journal-title":"Cancers (Basel)"},{"key":"54347_CR83","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/jdv.16766","volume":"35","author":"R V\u00e1raljai","year":"2021","unstructured":"V\u00e1raljai, R. et al. The predictive and prognostic significance of cell-free DNA concentration in melanoma. J. Eur. Acad. Dermatol. Venereol. 35, 387\u2013395. https:\/\/doi.org\/10.1111\/jdv.16766 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"54347_CR84","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/cmr.0000000000000716","volume":"31","author":"T Zhang","year":"2021","unstructured":"Zhang, T. et al. Diagnostic and prognostic value of heat shock protein 90\u03b1 in malignant melanoma. Melanoma Res 31, 152\u2013161. https:\/\/doi.org\/10.1097\/cmr.0000000000000716 (2021).","journal-title":"Melanoma Res"},{"key":"54347_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030702","author":"F Costa Svedman","year":"2022","unstructured":"Costa Svedman, F. et al. Plasma thymidine kinase activity as a novel biomarker in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14030702 (2022).","journal-title":"Cancers (Basel)"},{"key":"54347_CR86","doi-asserted-by":"publisher","first-page":"393","DOI":"10.5507\/bp.2021.053","volume":"166","author":"J Kopecky","year":"2022","unstructured":"Kopecky, J. et al. Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 166, 393\u2013404. https:\/\/doi.org\/10.5507\/bp.2021.053 (2022).","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"54347_CR87","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3892\/etm.2022.11495","volume":"24","author":"AA Musaelyan","year":"2022","unstructured":"Musaelyan, A. A. et al. Inflammatory and autoimmune predictive markers of response to anti-PD-1\/PD-L1 therapy in NSCLC and melanoma. Exp. Ther. Med. 24, 557. https:\/\/doi.org\/10.3892\/etm.2022.11495 (2022).","journal-title":"Exp. Ther. Med."},{"key":"54347_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092123","author":"P Rogala","year":"2022","unstructured":"Rogala, P. et al. Long term results and prognostic biomarkers for anti-PD1 immunotherapy used after BRAFi\/MEKi combination in advanced cutaneous melanoma patients. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14092123 (2022).","journal-title":"Cancers (Basel)"},{"key":"54347_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104235","author":"N Rossi","year":"2022","unstructured":"Rossi, N. et al. Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma. EBioMedicine https:\/\/doi.org\/10.1016\/j.ebiom.2022.104235 (2022).","journal-title":"EBioMedicine"},{"key":"54347_CR90","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.7150\/thno.77761","volume":"12","author":"CF Ruggiero","year":"2022","unstructured":"Ruggiero, C. F. et al. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma. Theranostics 12, 7420\u20137430. https:\/\/doi.org\/10.7150\/thno.77761 (2022).","journal-title":"Theranostics"},{"key":"54347_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051240","author":"M Trommer","year":"2022","unstructured":"Trommer, M. et al. Oncologic outcome and immune responses of radiotherapy with anti-PD-1 treatment for brain metastases regarding timing and benefiting subgroups. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14051240 (2022).","journal-title":"Cancers (Basel)"},{"key":"54347_CR92","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12094-021-02692-9","volume":"24","author":"CM Vila","year":"2022","unstructured":"Vila, C. M. et al. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution. Clin. Transl. Oncol. 24, 319\u2013330. https:\/\/doi.org\/10.1007\/s12094-021-02692-9 (2022).","journal-title":"Clin. Transl. Oncol."},{"key":"54347_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1083840","author":"J Zhao","year":"2022","unstructured":"Zhao, J. et al. Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1083840 (2022).","journal-title":"Front. Immunol."},{"key":"54347_CR94","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jmoldx.2023.06.014","volume":"25","author":"LG Aoude","year":"2023","unstructured":"Aoude, L. G. et al. Circulating tumor DNA: A promising biomarker for predicting recurrence in patients with BRAF-negative melanoma. J. Mol. Diagn. 25, 771\u2013781. https:\/\/doi.org\/10.1016\/j.jmoldx.2023.06.014 (2023).","journal-title":"J. Mol. Diagn."},{"key":"54347_CR95","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.34716","volume":"129","author":"Z Eroglu","year":"2023","unstructured":"Eroglu, Z. et al. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer 129, 1723\u20131734. https:\/\/doi.org\/10.1002\/cncr.34716 (2023).","journal-title":"Cancer"},{"key":"54347_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051542","author":"V Intern\u00f2","year":"2023","unstructured":"Intern\u00f2, V. et al. Melanoma brain metastases: A retrospective analysis of prognostic factors and efficacy of multimodal therapies. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers15051542 (2023).","journal-title":"Cancers (Basel)"},{"key":"54347_CR97","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1186\/s12967-023-04419-6","volume":"21","author":"D Mallardo","year":"2023","unstructured":"Mallardo, D. et al. CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy. J. Transl. Med. 21, 610. https:\/\/doi.org\/10.1186\/s12967-023-04419-6 (2023).","journal-title":"J. Transl. Med."},{"key":"54347_CR98","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1245\/s10434-013-2949-y","volume":"20","author":"KP Wevers","year":"2013","unstructured":"Wevers, K. P. et al. S-100B: A stronger prognostic biomarker than LDH in stage IIIB-C melanoma. Ann. Surg. Oncol. 20, 2772\u20132779. https:\/\/doi.org\/10.1245\/s10434-013-2949-y (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"54347_CR99","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00403-022-02425-0","volume":"315","author":"AD Desai","year":"2023","unstructured":"Desai, A. D. et al. An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: Prognostic capabilities and demographic variability. Arch. Dermatol. Res. 315, 799\u2013806. https:\/\/doi.org\/10.1007\/s00403-022-02425-0 (2023).","journal-title":"Arch. Dermatol. Res."},{"key":"54347_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081624","author":"B Weide","year":"2013","unstructured":"Weide, B. et al. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PLoS One https:\/\/doi.org\/10.1371\/journal.pone.0081624 (2013).","journal-title":"PLoS ONE"},{"key":"54347_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089218","author":"D Meckbach","year":"2014","unstructured":"Meckbach, D. et al. BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy. PLoS One https:\/\/doi.org\/10.1371\/journal.pone.0089218 (2014).","journal-title":"PLoS ONE"},{"key":"54347_CR102","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ejso.2010.12.013","volume":"37","author":"S Kruijff","year":"2011","unstructured":"Kruijff, S. et al. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection. Eur. J. Surg. Oncol. 37, 225\u2013232. https:\/\/doi.org\/10.1016\/j.ejso.2010.12.013 (2011).","journal-title":"Eur. J. Surg. Oncol."},{"key":"54347_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174158","author":"A Boerlin","year":"2022","unstructured":"Boerlin, A. et al. The prognostic value of a single, randomly timed circulating tumor DNA measurement in patients with metastatic melanoma. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14174158 (2022).","journal-title":"Cancers (Basel)"},{"key":"54347_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1117816","author":"D Machiraju","year":"2023","unstructured":"Machiraju, D. et al. Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma. Front Med (Lausanne) https:\/\/doi.org\/10.3389\/fmed.2023.1117816 (2023).","journal-title":"Front Med (Lausanne)"},{"key":"54347_CR105","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/1346-8138.15073","volume":"46","author":"A Tsutsumida","year":"2019","unstructured":"Tsutsumida, A. et al. Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma. J. Dermatol. 46, 947\u2013955. https:\/\/doi.org\/10.1111\/1346-8138.15073 (2019).","journal-title":"J. Dermatol."},{"key":"54347_CR106","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1249559","author":"V Damuzzo","year":"2016","unstructured":"Damuzzo, V. et al. Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. Oncoimmunology https:\/\/doi.org\/10.1080\/2162402x.2016.1249559 (2016).","journal-title":"Oncoimmunology"},{"key":"54347_CR107","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00008390-200506000-00009","volume":"15","author":"C Soubrane","year":"2005","unstructured":"Soubrane, C., Rixe, O., Meric, J. B., Khayat, D. & Mouawad, R. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: A retrospective study. Melanoma Res. 15, 199\u2013204. https:\/\/doi.org\/10.1097\/00008390-200506000-00009 (2005).","journal-title":"Melanoma Res."},{"key":"54347_CR108","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2217\/imt.11.97","volume":"3","author":"BJ Allen","year":"2011","unstructured":"Allen, B. J. et al. Analysis of patient survival in a Phase I trial of systemic targeted \u03b1-therapy for metastatic melanoma. Immunotherapy 3, 1041\u20131050. https:\/\/doi.org\/10.2217\/imt.11.97 (2011).","journal-title":"Immunotherapy"},{"key":"54347_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.10.029","volume":"88","author":"S Valpione","year":"2018","unstructured":"Valpione, S. et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur. J. Cancer 88, 1\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.029 (2018).","journal-title":"Eur. J. Cancer"},{"key":"54347_CR110","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00262-014-1528-9","volume":"63","author":"S Kelderman","year":"2014","unstructured":"Kelderman, S. et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol. Immunother. 63, 449\u2013458. https:\/\/doi.org\/10.1007\/s00262-014-1528-9 (2014).","journal-title":"Cancer Immunol Immunother"},{"key":"54347_CR111","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5114\/wo.2020.97607","volume":"24","author":"B Cybulska-Stopa","year":"2020","unstructured":"Cybulska-Stopa, B. et al. Real-world treatment practice in patients with advanced melanoma. Contemp. Oncol. (Pozn) 24, 118\u2013124. https:\/\/doi.org\/10.5114\/wo.2020.97607 (2020).","journal-title":"Contemp. Oncol. (Pozn)"},{"key":"54347_CR112","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/COC.0b013e318280d7be","volume":"37","author":"DM Marcus","year":"2014","unstructured":"Marcus, D. M. et al. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. Am. J. Clin. Oncol. 37, 580\u2013584. https:\/\/doi.org\/10.1097\/COC.0b013e318280d7be (2014).","journal-title":"Am. J. Clin. Oncol."},{"key":"54347_CR113","doi-asserted-by":"publisher","first-page":"7637","DOI":"10.1002\/cam4.2625","volume":"8","author":"JC Moser","year":"2019","unstructured":"Moser, J. C. et al. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF\/MEK inhibitors, anti-PD-1 antibodies, or nivolumab\/ipilimumab. Cancer Med. 8, 7637\u20137643. https:\/\/doi.org\/10.1002\/cam4.2625 (2019).","journal-title":"Cancer Med."},{"key":"54347_CR114","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ijrobp.2012.06.009","volume":"85","author":"R Partl","year":"2013","unstructured":"Partl, R., Richtig, E., Avian, A., Berghold, A. & Kapp, K. S. Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra- and extracranial metastases from malignant melanoma. Int. J. Radiat. Oncol. Biol. Phys. 85, 662\u2013666. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.06.009 (2013).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"54347_CR115","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00520-015-2793-7","volume":"24","author":"R Partl","year":"2016","unstructured":"Partl, R. et al. KPS\/LDH index: A simple tool for identifying patients with metastatic melanoma who are unlikely to benefit from palliative whole brain radiotherapy. Support Care Cancer 24, 523\u2013528. https:\/\/doi.org\/10.1007\/s00520-015-2793-7 (2016).","journal-title":"Support Care Cancer"},{"key":"54347_CR116","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00008390-199604000-00013","volume":"6","author":"U Keilholz","year":"1996","unstructured":"Keilholz, U., Scheibenbogen, C., Sommer, M., Pritsch, M. & Geuke, A. M. Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy. Melanoma Res. 6, 173\u2013178. https:\/\/doi.org\/10.1097\/00008390-199604000-00013 (1996).","journal-title":"Melanoma Res."},{"key":"54347_CR117","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1245\/s10434-020-08407-8","volume":"27","author":"AM Ibrahim","year":"2020","unstructured":"Ibrahim, A. M. et al. Imaging intensity and survival outcomes in high-risk resected melanoma treated by systemic therapy at recurrence. Ann. Surg. Oncol. 27, 3683\u20133691. https:\/\/doi.org\/10.1245\/s10434-020-08407-8 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"54347_CR118","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1002\/cam4.878","volume":"5","author":"L Khoja","year":"2016","unstructured":"Khoja, L. et al. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. Cancer Med. 5, 2792\u20132799. https:\/\/doi.org\/10.1002\/cam4.878 (2016).","journal-title":"Cancer Med."},{"key":"54347_CR119","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00268-013-2418-6","volume":"38","author":"FC Cananzi","year":"2014","unstructured":"Cananzi, F. C., Dalgleish, A. & Mudan, S. Surgical management of intraabdominal metastases from melanoma: Role of the neutrophil to lymphocyte ratio as a potential prognostic factor. World J. Surg. 38, 1542\u20131550. https:\/\/doi.org\/10.1007\/s00268-013-2418-6 (2014).","journal-title":"World J. Surg."},{"key":"54347_CR120","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/ijc.27991","volume":"133","author":"L Henry","year":"2013","unstructured":"Henry, L. et al. Clinical use of p-proteasome in discriminating metastatic melanoma patients: Comparative study with LDH, MIA and S100B protein. Int. J. Cancer 133, 142\u2013148. https:\/\/doi.org\/10.1002\/ijc.27991 (2013).","journal-title":"Int. J. Cancer"},{"key":"54347_CR121","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2021.05.031","volume":"154","author":"P Saiag","year":"2021","unstructured":"Saiag, P. et al. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. Eur. J. Cancer 154, 57\u201365. https:\/\/doi.org\/10.1016\/j.ejca.2021.05.031 (2021).","journal-title":"Eur. J. Cancer"},{"key":"54347_CR122","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejca.2022.07.035","volume":"175","author":"C Dutriaux","year":"2022","unstructured":"Dutriaux, C. et al. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases. Eur. J. Cancer 175, 254\u2013262. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.035 (2022).","journal-title":"Eur. J. Cancer"},{"key":"54347_CR123","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2217\/fon-2017-0714","volume":"14","author":"R Depenni","year":"2018","unstructured":"Depenni, R. et al. Dabrafenib-trametinib combination in \u201cfield-practice\u201d: An Italian experience. Future Oncol. 14, 2045\u20132052. https:\/\/doi.org\/10.2217\/fon-2017-0714 (2018).","journal-title":"Future Oncol."},{"key":"54347_CR124","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s10434-001-0116-3","volume":"8","author":"GA Porter","year":"2001","unstructured":"Porter, G. A. et al. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann. Surg. Oncol. 8, 116\u2013122. https:\/\/doi.org\/10.1007\/s10434-001-0116-3 (2001).","journal-title":"Ann. Surg. Oncol."},{"key":"54347_CR125","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/cmr.0000000000000526","volume":"29","author":"MA Wilson","year":"2019","unstructured":"Wilson, M. A. et al. Impact of initial stage on metastatic melanoma survival. Melanoma Res. 29, 281\u2013288. https:\/\/doi.org\/10.1097\/cmr.0000000000000526 (2019).","journal-title":"Melanoma Res."},{"key":"54347_CR126","doi-asserted-by":"publisher","DOI":"10.1177\/03008916231179251","author":"M Aglietta","year":"2023","unstructured":"Aglietta, M. et al. Outcomes in patients with BRAF(V600)-mutated melanoma and brain metastases at baseline treated with Dabrafenib plus Trametinib. Tumori https:\/\/doi.org\/10.1177\/03008916231179251 (2023).","journal-title":"Tumori"},{"key":"54347_CR127","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/bjc.2012.306","volume":"107","author":"B Weide","year":"2012","unstructured":"Weide, B. et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br. J. Cancer 107, 422\u2013428. https:\/\/doi.org\/10.1038\/bjc.2012.306 (2012).","journal-title":"Br. J. Cancer"},{"key":"54347_CR128","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/CMR.0b013e328315c690","volume":"18","author":"A Bolander","year":"2008","unstructured":"Bolander, A. et al. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma. Melanoma Res. 18, 412\u2013419. https:\/\/doi.org\/10.1097\/CMR.0b013e328315c690 (2008).","journal-title":"Melanoma Res."},{"key":"54347_CR129","first-page":"595","volume":"27","author":"MG Cao","year":"2007","unstructured":"Cao, M. G. et al. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer. Res 27, 595\u2013599 (2007).","journal-title":"Anticancer Res"},{"key":"54347_CR130","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1245\/aso.2002.9.2.120","volume":"9","author":"MH Chung","year":"2002","unstructured":"Chung, M. H. Serum TA90 immune complex assay can predict outcome after resection of thick (\u22654 mm) primary melanoma and sentinel lymphadenectomy. Ann. Surg. Oncol. 9, 120\u2013126. https:\/\/doi.org\/10.1245\/aso.2002.9.2.120 (2002).","journal-title":"Ann. Surg. Oncol."},{"key":"54347_CR131","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/annonc\/mdy229","volume":"29","author":"PG Corrie","year":"2018","unstructured":"Corrie, P. G. et al. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: Survival analysis of the AVAST-M trial. Ann. Oncol. 29, 1843\u20131852. https:\/\/doi.org\/10.1093\/annonc\/mdy229 (2018).","journal-title":"Ann. Oncol."},{"key":"54347_CR132","doi-asserted-by":"publisher","first-page":"532","DOI":"10.5114\/wo.2012.32487","volume":"16","author":"B Cybulska-Stopa","year":"2012","unstructured":"Cybulska-Stopa, B. et al. Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. Contemp. Oncol. (Pozn) 16, 532\u2013545. https:\/\/doi.org\/10.5114\/wo.2012.32487 (2012).","journal-title":"Contemp Oncol (Pozn)"},{"key":"54347_CR133","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.ejso.2020.07.011","volume":"46","author":"EA Deckers","year":"2020","unstructured":"Deckers, E. A. et al. The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients. Eur. J. Surg. Oncol. 46, 2147\u20132153. https:\/\/doi.org\/10.1016\/j.ejso.2020.07.011 (2020).","journal-title":"Eur. J. Surg. Oncol."},{"key":"54347_CR134","unstructured":"Decoster, L. et al. Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma. Anticancer. Res. 35, 6893\u20136899 (2015)."},{"key":"54347_CR135","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000110424","volume":"28","author":"J Domingo-Dom\u00e8nech","year":"2007","unstructured":"Domingo-Dom\u00e8nech, J. et al. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour. Biol. 28, 264\u2013272. https:\/\/doi.org\/10.1159\/000110424 (2007).","journal-title":"Tumour. Biol."},{"key":"54347_CR136","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/jco.2015.64.1357","volume":"34","author":"S Fang","year":"2016","unstructured":"Fang, S. et al. Association of Vitamin D levels with outcome in patients with melanoma after adjustment for C-Reactive Protein. J. Clin. Oncol. 34, 1741\u20131747. https:\/\/doi.org\/10.1200\/jco.2015.64.1357 (2016).","journal-title":"J. Clin. Oncol."},{"key":"54347_CR137","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/bf02524351","volume":"11","author":"MB Faries","year":"2004","unstructured":"Faries, M. B., Gupta, R. K., Ye, X., Hsueh, E. C. & Morton, D. L. Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of American Joint Committee on Cancer stage III melanoma. Ann. Surg. Oncol. 11, 85\u201393. https:\/\/doi.org\/10.1007\/bf02524351 (2004).","journal-title":"Ann. Surg. Oncol."},{"key":"54347_CR138","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.intimp.2016.09.030","volume":"40","author":"J Felix","year":"2016","unstructured":"Felix, J. et al. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. Int. Immunopharmacol. 40, 466\u2013473. https:\/\/doi.org\/10.1016\/j.intimp.2016.09.030 (2016).","journal-title":"Int. Immunopharmacol."},{"key":"54347_CR139","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/annonc\/mdw134","volume":"27","author":"MH Geukes Foppen","year":"2016","unstructured":"Geukes Foppen, M. H. et al. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Ann. Oncol. 27, 1138\u20131142. https:\/\/doi.org\/10.1093\/annonc\/mdw134 (2016).","journal-title":"Ann. Oncol."},{"key":"54347_CR140","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.2147\/OTT.S248237","volume":"13","author":"A Forschner","year":"2020","unstructured":"Forschner, A. et al. Circulating tumor DNA correlates with outcome in metastatic melanoma treated by braf and mek inhibitors \u2013 Results of a prospective biomarker study. Oncol. Targets Ther. 13, 5017\u20135032. https:\/\/doi.org\/10.2147\/OTT.S248237 (2020).","journal-title":"OncoTargets Ther."},{"key":"54347_CR141","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000135492","volume":"31","author":"F Egberts","year":"2008","unstructured":"Egberts, F. et al. Long-term survival analysis in metastatic melanoma: Serum S100B is an independent prognostic marker and superior to LDH. Onkologie 31, 380\u2013384. https:\/\/doi.org\/10.1159\/000135492 (2008).","journal-title":"Onkologie"},{"key":"54347_CR142","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1016\/j.ejca.2009.09.004","volume":"45","author":"A Fusi","year":"2009","unstructured":"Fusi, A. et al. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur. J. Cancer 45, 3189\u20133197. https:\/\/doi.org\/10.1016\/j.ejca.2009.09.004 (2009).","journal-title":"Eur. J. Cancer"},{"key":"54347_CR143","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.cmr.0000200491.00841.5f","volume":"16","author":"M Guida","year":"2006","unstructured":"Guida, M. et al. Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Res. 16, 317\u2013323. https:\/\/doi.org\/10.1097\/01.cmr.0000200491.00841.5f (2006).","journal-title":"Melanoma Res."},{"key":"54347_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-1-13","author":"M Guida","year":"2003","unstructured":"Guida, M. et al. Fibrinogen: A novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (Italian melanoma inter-group) trial. J. Transl. Med. https:\/\/doi.org\/10.1186\/1479-5876-1-13 (2003).","journal-title":"J. Transl. Med."},{"key":"54347_CR145","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/j.1600-0625.2010.01151.x","volume":"19","author":"L Henry","year":"2010","unstructured":"Henry, L. et al. Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma. Exp. Dermatol. 19, 1054\u20131059. https:\/\/doi.org\/10.1111\/j.1600-0625.2010.01151.x (2010).","journal-title":"Exp. Dermatol."},{"key":"54347_CR146","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/j.1346-8138.2011.01219.x","volume":"38","author":"MA Hofmann","year":"2011","unstructured":"Hofmann, M. A. et al. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients. J. Dermatol. 38, 880\u2013886. https:\/\/doi.org\/10.1111\/j.1346-8138.2011.01219.x (2011).","journal-title":"J. Dermatol."},{"key":"54347_CR147","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1200\/JCO.2011.40.0887","volume":"30","author":"S Hoshimoto","year":"2012","unstructured":"Hoshimoto, S. et al. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J. Clin. Oncol. 30, 3819\u20133826. https:\/\/doi.org\/10.1200\/JCO.2011.40.0887 (2012).","journal-title":"J. Clin. Oncol."},{"key":"54347_CR148","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1691","volume":"6","author":"HP Hu","year":"2023","unstructured":"Hu, H. P., Archer, C., Yip, D. & Peters, G. Clinical predictors of survival in real world practice in stage IV melanoma. Cancer Rep. (Hoboken) 6, e1691. https:\/\/doi.org\/10.1002\/cnr2.1691 (2023).","journal-title":"Cancer Rep (Hoboken)"},{"key":"54347_CR149","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000531","author":"S Iivanainen","year":"2019","unstructured":"Iivanainen, S., Ahvonen, J., Knuuttila, A., Tiainen, S. & Koivunen, J. P. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. ESMO Open https:\/\/doi.org\/10.1136\/esmoopen-2019-000531 (2019).","journal-title":"ESMO Open"},{"key":"54347_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112922","author":"OJ van Not","year":"2023","unstructured":"van Not, O. J. et al. A survival tree of advanced melanoma patients with brain metastases treated with immune checkpoint inhibitors. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers15112922 (2023).","journal-title":"Cancers (Basel)"},{"key":"54347_CR151","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2340\/00015555-3080","volume":"99","author":"L Keller","year":"2019","unstructured":"Keller, L. et al. Early circulating tumour DNA variations predict tumour response in melanoma patients treated with immunotherapy. Acta Derm. Venereol. 99, 206\u2013210. https:\/\/doi.org\/10.2340\/00015555-3080 (2019).","journal-title":"Acta Derm. Venereol."},{"key":"54347_CR152","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/jid.2012.468","volume":"133","author":"L Khoja","year":"2013","unstructured":"Khoja, L. et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J. Invest. Dermatol. 133, 1582\u20131590. https:\/\/doi.org\/10.1038\/jid.2012.468 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"54347_CR153","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1158\/1078-0432.Ccr-10-0037","volume":"16","author":"K Koyanagi","year":"2010","unstructured":"Koyanagi, K. et al. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin. Cancer Res. 16, 2402\u20132408. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-0037 (2010).","journal-title":"Clin. Cancer Res."},{"key":"54347_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153706","author":"L Levati","year":"2022","unstructured":"Levati, L. et al. Circulating miR-1246 and miR-485-3p as promising biomarkers of clinical response and outcome in melanoma patients treated with targeted therapy. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14153706 (2022).","journal-title":"Cancers (Basel)"},{"key":"54347_CR155","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.12659\/msm.891327","volume":"20","author":"P Li","year":"2014","unstructured":"Li, P., He, Q. Y., Luo, C. Q. & Qian, L. Y. Circulating miR-221 expression level and prognosis of cutaneous malignant melanoma. Med. Sci. Monit. 20, 2472\u20132477. https:\/\/doi.org\/10.12659\/msm.891327 (2014).","journal-title":"Med. Sci. Monit."},{"key":"54347_CR156","doi-asserted-by":"publisher","first-page":"324","DOI":"10.12659\/msm.904770","volume":"24","author":"J Li","year":"2018","unstructured":"Li, J., Fu, W., Zhang, W. & Li, P. High number of circulating tumor cells predicts poor survival of cutaneous melanoma patients in China. Med. Sci. Monit. 24, 324\u2013331. https:\/\/doi.org\/10.12659\/msm.904770 (2018).","journal-title":"Med. Sci. Monit."},{"key":"54347_CR157","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000024840","author":"C Li","year":"2021","unstructured":"Li, C. et al. The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population. Medicine (Baltimore) https:\/\/doi.org\/10.1097\/md.0000000000024840 (2021).","journal-title":"Medicine (Baltimore)"},{"key":"54347_CR158","doi-asserted-by":"publisher","unstructured":"Lin, S. Y. et al. Multiplex Gene Profiling of Cell-Free DNA in Patients With Metastatic Melanoma for Monitoring Disease. JCO Precis Oncol. 2 https:\/\/doi.org\/10.1200\/po.17.00225 (2018).","DOI":"10.1200\/po.17.00225"},{"key":"54347_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110092","author":"L Lu","year":"2023","unstructured":"Lu, L. et al. Dynamic changes of circulating soluble PD-1\/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. Int. Immunopharmacol. https:\/\/doi.org\/10.1016\/j.intimp.2023.110092 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"54347_CR160","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.Ccr-19-2670","volume":"26","author":"A Lucci","year":"2020","unstructured":"Lucci, A. et al. Circulating tumor cells and early relapse in node-positive melanoma. Clin. Cancer Res. 26, 1886\u20131895. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2670 (2020).","journal-title":"Clin. Cancer Res."},{"key":"54347_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143630","author":"A Lucci","year":"2023","unstructured":"Lucci, A. et al. Presence of circulating tumor cells predates imaging detection of relapse in patients with stage III melanoma. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers15143630 (2023).","journal-title":"Cancers (Basel)"},{"key":"54347_CR162","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/sj.bjc.6605622","volume":"102","author":"M Staudt","year":"2010","unstructured":"Staudt, M. et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br. J. Cancer 102, 1213\u20131218. https:\/\/doi.org\/10.1038\/sj.bjc.6605622 (2010).","journal-title":"Br. J. Cancer"},{"key":"54347_CR163","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","volume":"28","author":"MF Sanmamed","year":"2017","unstructured":"Sanmamed, M. F. et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann. Oncol. 28, 1988\u20131995. https:\/\/doi.org\/10.1093\/annonc\/mdx190 (2017).","journal-title":"Ann. Oncol."},{"key":"54347_CR164","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00280-014-2479-8","volume":"74","author":"D Mahalingam","year":"2014","unstructured":"Mahalingam, D. et al. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemother. Pharmacol. 74, 77\u201384. https:\/\/doi.org\/10.1007\/s00280-014-2479-8 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"54347_CR165","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/00008390-200112000-00009","volume":"11","author":"R Meral","year":"2001","unstructured":"Meral, R. et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res. 11, 627\u2013632. https:\/\/doi.org\/10.1097\/00008390-200112000-00009 (2001).","journal-title":"Melanoma Res."},{"key":"54347_CR166","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/cmr.0000000000000907","volume":"33","author":"G Pelizzari","year":"2023","unstructured":"Pelizzari, G. et al. Estimating survival in patients with melanoma brain metastases: Prognostic value of lactate dehydrogenase. Melanoma Res. 33, 398\u2013405. https:\/\/doi.org\/10.1097\/cmr.0000000000000907 (2023).","journal-title":"Melanoma Res."},{"key":"54347_CR167","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00262-015-1686-4","volume":"64","author":"L Prasmickaite","year":"2015","unstructured":"Prasmickaite, L. et al. Evaluation of serum osteopontin level and gene polymorphism as biomarkers: Analyses from the Nordic Adjuvant Interferon alpha Melanoma trial. Cancer Immunol. Immunother. 64, 769\u2013776. https:\/\/doi.org\/10.1007\/s00262-015-1686-4 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"54347_CR168","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3892\/ijo.2011.896","volume":"38","author":"C Rao","year":"2011","unstructured":"Rao, C. et al. Circulating melanoma cells and survival in metastatic melanoma. Int. J. Oncol. 38, 755\u2013760. https:\/\/doi.org\/10.3892\/ijo.2011.896 (2011).","journal-title":"Int. J. Oncol."},{"key":"54347_CR169","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jamcollsurg.2018.04.026","volume":"227","author":"CS Hall","year":"2018","unstructured":"Hall, C. S. et al. Circulating tumor cells in Stage IV melanoma patients. J. Am. Coll. Surg. 227, 116\u2013124. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2018.04.026 (2018).","journal-title":"J. Am. Coll. Surg."},{"key":"54347_CR170","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem, S. et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br. J. Cancer 114, 256\u2013261. https:\/\/doi.org\/10.1038\/bjc.2015.467 (2016).","journal-title":"Br. J. Cancer"},{"key":"54347_CR171","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.cca.2013.11.034","volume":"429","author":"MF Sanmamed","year":"2014","unstructured":"Sanmamed, M. F. et al. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clin. Chim. Acta 429, 168\u2013174. https:\/\/doi.org\/10.1016\/j.cca.2013.11.034 (2014).","journal-title":"Clin. Chim. Acta"},{"key":"54347_CR172","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1373\/clinchem.2014.230235","volume":"61","author":"MF Sanmamed","year":"2015","unstructured":"Sanmamed, M. F. et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin. Chem. 61, 297\u2013304. https:\/\/doi.org\/10.1373\/clinchem.2014.230235 (2015).","journal-title":"Clin. Chem."},{"key":"54347_CR173","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/jco.2005.03.7960","volume":"24","author":"H Schmidt","year":"2006","unstructured":"Schmidt, H. et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J. Clin. Oncol. 24, 798\u2013804. https:\/\/doi.org\/10.1200\/jco.2005.03.7960 (2006).","journal-title":"J. Clin. Oncol."},{"key":"54347_CR174","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040634","author":"M Schneider","year":"2021","unstructured":"Schneider, M. et al. Prognostic value of preoperative inflammatory markers in melanoma patients with brain metastases. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm10040634 (2021).","journal-title":"J. Clin. Med."},{"key":"54347_CR175","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000335000","volume":"81","author":"N Seetharamu","year":"2011","unstructured":"Seetharamu, N. et al. Enrollment in clinical trials correlates with improved survival in metastatic melanoma. Oncology 81, 403\u2013409. https:\/\/doi.org\/10.1159\/000335000 (2011).","journal-title":"Oncology"},{"key":"54347_CR176","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1002\/onco.13562","volume":"26","author":"KP Shah","year":"2021","unstructured":"Shah, K. P., Song, H., Ye, F. & Johnson, D. B. Prognostic clinical and radiographic biomarkers for BRAF-targeted therapy in advanced melanoma. Oncologist 26, e333\u2013e335. https:\/\/doi.org\/10.1002\/onco.13562 (2021).","journal-title":"Oncologist"},{"key":"54347_CR177","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1373\/clinchem.2018.290023","volume":"64","author":"S Silva","year":"2018","unstructured":"Silva, S. et al. Genome-wide analysis of circulating cell-free DNA copy number detects active melanoma and predicts survival. Clin. Chem. 64, 1338\u20131346. https:\/\/doi.org\/10.1373\/clinchem.2018.290023 (2018).","journal-title":"Clin. Chem."},{"key":"54347_CR178","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/290536","volume":"2012","author":"S Sivan","year":"2012","unstructured":"Sivan, S. et al. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin. Dev. Immunol. 2012, 290536. https:\/\/doi.org\/10.1155\/2012\/290536 (2012).","journal-title":"Clin. Dev. Immunol."},{"key":"54347_CR179","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ejca.2004.10.019","volume":"41","author":"LH Smit","year":"2005","unstructured":"Smit, L. H. et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur. J. Cancer 41, 386\u2013392. https:\/\/doi.org\/10.1016\/j.ejca.2004.10.019 (2005).","journal-title":"Eur. J. Cancer"},{"key":"54347_CR180","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/jco.2008.17.1777","volume":"27","author":"AA Tarhini","year":"2009","unstructured":"Tarhini, A. A., Stuckert, J., Lee, S., Sander, C. & Kirkwood, J. M. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J. Clin. Oncol. 27, 38\u201344. https:\/\/doi.org\/10.1200\/jco.2008.17.1777 (2009).","journal-title":"J. Clin. Oncol."},{"key":"54347_CR181","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1200\/jco.1996.14.5.1697","volume":"14","author":"E Tartour","year":"1996","unstructured":"Tartour, E. et al. Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: A French multiinstitutional study. J. Clin. Oncol. 14, 1697\u20131703. https:\/\/doi.org\/10.1200\/jco.1996.14.5.1697 (1996).","journal-title":"J. Clin. Oncol."},{"key":"54347_CR182","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1385\/mo:22:3:241","volume":"22","author":"F Tas","year":"2005","unstructured":"Tas, F. et al. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: Serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med. Oncol. 22, 241\u2013246. https:\/\/doi.org\/10.1385\/mo:22:3:241 (2005).","journal-title":"Med. Oncol."},{"key":"54347_CR183","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004226","author":"HA Tawbi","year":"2022","unstructured":"Tawbi, H. A. et al. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: Exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). J. Immunother. Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004226 (2022).","journal-title":"J. Immunother. Cancer."},{"key":"54347_CR184","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/jco.2001.19.2.577","volume":"19","author":"S Ugurel","year":"2001","unstructured":"Ugurel, S., Rappl, G., Tilgen, W. & Reinhold, U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 19, 577\u2013583. https:\/\/doi.org\/10.1200\/jco.2001.19.2.577 (2001).","journal-title":"J. Clin. Oncol."},{"key":"54347_CR185","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/1346-8138.13651","volume":"44","author":"H Umemura","year":"2017","unstructured":"Umemura, H. et al. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma. J. Dermatol. 44, 449\u2013454. https:\/\/doi.org\/10.1111\/1346-8138.13651 (2017).","journal-title":"J. Dermatol."},{"key":"54347_CR186","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/CJI.0b013e31828eed39","volume":"36","author":"S Wilgenhof","year":"2013","unstructured":"Wilgenhof, S. et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J. Immunother. 36, 215\u2013222. https:\/\/doi.org\/10.1097\/CJI.0b013e31828eed39 (2013).","journal-title":"J. Immunother."},{"key":"54347_CR187","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/2326-6066.Cir-16-0206","volume":"5","author":"X Wu","year":"2017","unstructured":"Wu, X. et al. Angiopoietin-2 as a biomarker and target for immune checkpoint therapy. Cancer Immunol. Res. 5, 17\u201328. https:\/\/doi.org\/10.1158\/2326-6066.Cir-16-0206 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"54347_CR188","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1440930","author":"X Wu","year":"2018","unstructured":"Wu, X. et al. Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. Oncoimmunology https:\/\/doi.org\/10.1080\/2162402x.2018.1440930 (2018).","journal-title":"Oncoimmunology"},{"key":"54347_CR189","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030702","author":"VAS Schildbach","year":"2023","unstructured":"Schildbach, V. A. S. et al. C-Reactive Protein and lymphocyte-to-monocyte ratio predict recurrence in Stage III melanoma patients with microscopic sentinel lymph node metastasis. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers15030702 (2023).","journal-title":"Cancers (Basel)"},{"key":"54347_CR190","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdz048","volume":"30","author":"L Tan","year":"2019","unstructured":"Tan, L. et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann. Oncol. 30, 804\u2013814. https:\/\/doi.org\/10.1093\/annonc\/mdz048 (2019).","journal-title":"Ann. Oncol."},{"key":"54347_CR191","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/annonc\/mdz075","volume":"30","author":"JH Lee","year":"2019","unstructured":"Lee, J. H. et al. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Ann. Oncol. 30, 815\u2013822. https:\/\/doi.org\/10.1093\/annonc\/mdz075 (2019).","journal-title":"Ann. Oncol."},{"key":"54347_CR192","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/cmr.0000000000000453","volume":"28","author":"MG Schouwenburg","year":"2018","unstructured":"Schouwenburg, M. G. et al. Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: Prognostic factors associated with clinical outcomes. Melanoma Res. 28, 326\u2013332. https:\/\/doi.org\/10.1097\/cmr.0000000000000453 (2018).","journal-title":"Melanoma Res."},{"key":"54347_CR193","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3892\/or.2013.2666","volume":"30","author":"A Filia","year":"2013","unstructured":"Filia, A. et al. Plasma osteopontin concentrations in patients with cutaneous melanoma. Oncol. Rep. 30, 1575\u20131580. https:\/\/doi.org\/10.3892\/or.2013.2666 (2013).","journal-title":"Oncol. Rep."},{"key":"54347_CR194","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000029536","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Liu, B., Kotenko, S. & Li, W. Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Medicine (Baltimore) https:\/\/doi.org\/10.1097\/md.0000000000029536 (2022).","journal-title":"Medicine (Baltimore)"},{"key":"54347_CR195","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000025318","author":"J Xu","year":"2021","unstructured":"Xu, J., Zhao, J., Wang, J., Sun, C. & Zhu, X. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1\/PD-L1 therapy: A meta-analysis. Medicine (Baltimore) https:\/\/doi.org\/10.1097\/md.0000000000025318 (2021).","journal-title":"Medicine (Baltimore)"},{"key":"54347_CR196","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jaad.2022.02.024","volume":"87","author":"MS Asdourian","year":"2022","unstructured":"Asdourian, M. S. et al. Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. J. Am. Acad. Dermatol. 87, 1147\u20131149. https:\/\/doi.org\/10.1016\/j.jaad.2022.02.024 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"54347_CR197","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/cmr.0000000000000461","volume":"28","author":"P Teterycz","year":"2018","unstructured":"Teterycz, P. et al. High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. Melanoma Res. 28, 435\u2013441. https:\/\/doi.org\/10.1097\/cmr.0000000000000461 (2018).","journal-title":"Melanoma Res."},{"key":"54347_CR198","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-328","author":"B Peric","year":"2011","unstructured":"Peric, B., Zagar, I., Novakovic, S., Zgajnar, J. & Hocevar, M. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer https:\/\/doi.org\/10.1186\/1471-2407-11-328 (2011).","journal-title":"BMC Cancer"},{"key":"54347_CR199","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/ott.S153290","volume":"11","author":"DB Sacdalan","year":"2018","unstructured":"Sacdalan, D. B., Lucero, J. A. & Sacdalan, D. L. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: A review and meta-analysis. Onco. Targets. Ther. 11, 955\u2013965. https:\/\/doi.org\/10.2147\/ott.S153290 (2018).","journal-title":"Onco. Targets. Ther."},{"key":"54347_CR200","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215297","author":"Y Guo","year":"2022","unstructured":"Guo, Y., Xiang, D., Wan, J., Yang, L. & Zheng, C. Focus on the dynamics of neutrophil-to-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A meta-analysis and systematic review. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14215297 (2022).","journal-title":"Cancers (Basel)"},{"key":"54347_CR201","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/CMR.0b013e3283543d72","volume":"22","author":"L Hoejberg","year":"2012","unstructured":"Hoejberg, L., Bastholt, L. & Schmidt, H. Interleukin-6 and melanoma. Melanoma Res. 22, 327\u2013333. https:\/\/doi.org\/10.1097\/CMR.0b013e3283543d72 (2012).","journal-title":"Melanoma Res."},{"key":"54347_CR202","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02422-5","volume":"41","author":"AH Mohamed","year":"2024","unstructured":"Mohamed, A. H. et al. Interleukin-6 serves as a critical factor in various cancer progression and therapy. Med. Oncol. 41, 182. https:\/\/doi.org\/10.1007\/s12032-024-02422-5 (2024).","journal-title":"Med. Oncol."},{"key":"54347_CR203","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03971-5","volume":"21","author":"D Mallardo","year":"2023","unstructured":"Mallardo, D. et al. IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab. J. Transl. Med. 21, 140. https:\/\/doi.org\/10.1186\/s12967-023-03971-5 (2023).","journal-title":"J. Transl. Med."},{"key":"54347_CR204","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41591-021-01458-8","volume":"27","author":"P Hegyi","year":"2021","unstructured":"Hegyi, P., Er\u0151ss, B., Izb\u00e9ki, F., P\u00e1rniczky, A. & Szentesi, A. Accelerating the translational medicine cycle: The Academia Europaea pilot. Nat. Med. 27, 1317\u20131319. https:\/\/doi.org\/10.1038\/s41591-021-01458-8 (2021).","journal-title":"Nat. Med."},{"key":"54347_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051532","author":"P Hegyi","year":"2020","unstructured":"Hegyi, P. et al. Academia Europaea position paper on translational medicine: The cycle model for translating scientific results into community benefits. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm9051532 (2020).","journal-title":"J. Clin. Med."},{"key":"54347_CR206","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1281940","author":"J Li","year":"2024","unstructured":"Li, J., Dan, K. & Ai, J. Machine learning in the prediction of immunotherapy response and prognosis of melanoma: A systematic review and meta-analysis. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1281940 (2024).","journal-title":"Front. Immunol."},{"key":"54347_CR207","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/s0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E. & Scolyer, R. A. Cutaneous melanoma. Lancet 402, 485\u2013502. https:\/\/doi.org\/10.1016\/s0140-6736(23)00821-8 (2023).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54347-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:07:10Z","timestamp":1787180830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54347-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":207,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54347"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54347-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26099"}}